Concepedia

Author

Min‐Hee Ryu

Asan Medical CenterORCID

Also Known As

Carlos Gomez-Martin, Gyeong-Won Lee, H. Chang, J. J. Lee, Keun-Wook Lee, M -H Ryu, M H Ryu, M. H. Ryu, M. Ryu, M.-H Ryu

517

Publications

19.6K

Citations

58

H-Index

94

Concepts

All Affiliations

Asan Medical CenterUniversity of UlsanUlsan CollegeYonsei UniversitySungkyunkwan University
MR

About

Min‐Hee Ryu is an author at Asan Medical Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

42

116

10.5K

2

Health Sciences

19

25

2.1K

3

Public Health

1

1

61

4

Social Sciences

1

1

41

5

Biostatistics

1

1

61

Min‐Hee Ryu

×

207

Publications

16.3K

Citations

57

H-Index

YearCitations

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Narikazu Boku, Taroh Satoh,

The Lancet

2017

2.2K

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang,

The Lancet

2018

1.3K

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

Kohei Shitara, Yung‐Jue Bang, Satoru Iwasa,

New England Journal of Medicine

2020

1.2K

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Li‐Tzong Chen, Min‐Hee Ryu,

The Lancet Oncology

2022

712

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Sun Young Rha, Do‐Youn Oh, Patricio Yañez,

The Lancet Oncology

2023

521

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

Yu Jeong Bang, Eduardo Yañez Ruiz, Eric Van Cutsem,

Annals of Oncology

2018

495

PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer

Yoon‐Koo Kang, Jeong Hwan Yook, Young-Kyu Park,

Journal of Clinical Oncology

2021

332

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)

Narikazu Boku, Min‐Hee Ryu, Ken Kato,

Annals of Oncology

2018

317

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

Kei Muro, Florian Lordick, Takahiro Tsushima,

Annals of Oncology

2018

284

A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data

Li‐Tzong Chen, Taroh Satoh, Min‐Hee Ryu,

Gastric Cancer

2019

223

Page 1